JP6522337B2 - 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 - Google Patents

細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 Download PDF

Info

Publication number
JP6522337B2
JP6522337B2 JP2014510520A JP2014510520A JP6522337B2 JP 6522337 B2 JP6522337 B2 JP 6522337B2 JP 2014510520 A JP2014510520 A JP 2014510520A JP 2014510520 A JP2014510520 A JP 2014510520A JP 6522337 B2 JP6522337 B2 JP 6522337B2
Authority
JP
Japan
Prior art keywords
compstatin
compstatin analog
moiety
cell
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014510520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514364A (ja
JP2014514364A5 (cg-RX-API-DMAC7.html
Inventor
セドリック・フランソワ
パスカル・デシャテレッツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of JP2014514364A publication Critical patent/JP2014514364A/ja
Publication of JP2014514364A5 publication Critical patent/JP2014514364A5/ja
Application granted granted Critical
Publication of JP6522337B2 publication Critical patent/JP6522337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014510520A 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 Active JP6522337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484836P 2011-05-11 2011-05-11
US61/484,836 2011-05-11
PCT/US2012/037648 WO2012155107A1 (en) 2011-05-11 2012-05-11 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111625A Division JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Publications (3)

Publication Number Publication Date
JP2014514364A JP2014514364A (ja) 2014-06-19
JP2014514364A5 JP2014514364A5 (cg-RX-API-DMAC7.html) 2018-11-29
JP6522337B2 true JP6522337B2 (ja) 2019-05-29

Family

ID=47139714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014510520A Active JP6522337B2 (ja) 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2017111625A Active JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2019129901A Active JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017111625A Active JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2019129901A Active JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Country Status (13)

Country Link
US (4) US10125171B2 (cg-RX-API-DMAC7.html)
EP (2) EP2707384B1 (cg-RX-API-DMAC7.html)
JP (3) JP6522337B2 (cg-RX-API-DMAC7.html)
CN (2) CN103687867B (cg-RX-API-DMAC7.html)
AU (3) AU2012253294B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013028816B1 (cg-RX-API-DMAC7.html)
CA (1) CA2835627C (cg-RX-API-DMAC7.html)
DK (1) DK2707384T3 (cg-RX-API-DMAC7.html)
ES (1) ES2915265T3 (cg-RX-API-DMAC7.html)
IL (3) IL265344B2 (cg-RX-API-DMAC7.html)
MX (2) MX385001B (cg-RX-API-DMAC7.html)
RU (1) RU2653439C9 (cg-RX-API-DMAC7.html)
WO (1) WO2012155107A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024056923A (ja) * 2012-11-15 2024-04-23 アペリス・ファーマシューティカルズ・インコーポレイテッド 細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2461241A1 (en) 2010-12-03 2012-06-06 Research In Motion Limited Soft key with main function and logically related sub-functions for touch screen device
US10125171B2 (en) * 2011-05-11 2018-11-13 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
WO2014152391A1 (en) * 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2016138520A1 (en) * 2015-02-27 2016-09-01 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
FI3359555T3 (fi) * 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
EP3373978A4 (en) 2015-11-12 2019-06-26 Graybug Vision, Inc. AGGREGATION OF MICROPARTICLES FOR THERAPY
CN105777893B (zh) * 2016-03-24 2019-10-25 杭州亚慧生物科技有限公司 一种高强度血清白蛋白骨修复材料及其制备方法
US11338013B2 (en) * 2016-10-17 2022-05-24 Apellis Pharmaceuticals, Inc. Combination therapy for C3 inhibition
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
MX2019010381A (es) 2017-03-01 2020-01-21 Achillion Pharmaceuticals Inc Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
WO2018209155A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
CN107722262B (zh) * 2017-09-18 2020-11-24 华南理工大学 一种聚碳二亚胺类聚合物及其制备方法与应用
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
PL3645550T3 (pl) 2018-04-06 2022-04-04 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o zwiększonej rozpuszczalności i ulepszonych właściwościach farmakokinetycznych
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
AU2019406830A1 (en) 2018-12-17 2021-07-08 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CN110624274B (zh) * 2019-08-27 2021-04-13 苏州赛分科技有限公司 分离介质及其制备方法和应用
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2022066774A1 (en) 2020-09-23 2022-03-31 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2023081318A2 (en) * 2021-11-03 2023-05-11 Apellis Pharmaceuticals, Inc. Complement inhibitor dosing regimens
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
WO1997033603A1 (en) 1996-03-13 1997-09-18 Trustees Of The University Of Pennsylvania Novel peptides which inhibit complement activation
CA2286692A1 (en) 1997-04-11 1998-10-22 President And Fellows Of Harvard College Polymeric conjugates polyvalently presenting an agent for therapy
AU6957098A (en) 1997-04-11 1998-11-11 Advanced Medicine, Inc. Polyvalent presenter combinatorial libraries and their uses
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
US6214790B1 (en) 1998-04-10 2001-04-10 Mayo Foundation For Medical Education And Research Neo-tryptophan
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2373649T3 (es) 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
DK1951279T3 (en) 2005-10-08 2017-07-31 Apellis Pharmaceuticals Inc COMPSTATIN AND ANALOGUES THEREOF FOR EYE DISEASES
US20070134244A1 (en) 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP5302004B2 (ja) 2005-11-28 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 強力なコンプスタチン類似体
CL2007003044A1 (es) 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
EA200901451A1 (ru) 2007-07-19 2010-06-30 Элексел, Инк. Самособирающиеся амфифильные полимеры в качестве противоопухолевых средств
US20110092446A1 (en) 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
RU2505311C2 (ru) 2007-10-02 2014-01-27 Потентия Фармасьютикалз, Инк. Пролонгированная доставка аналогов компстатина из гелей
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
CA2760839C (en) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US8625635B2 (en) 2010-04-26 2014-01-07 Cleversafe, Inc. Dispersed storage network frame protocol header
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012006599A2 (en) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
WO2012040259A2 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
US10125171B2 (en) * 2011-05-11 2018-11-13 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
AU2012304442B2 (en) 2011-09-07 2017-05-25 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
WO2014078734A2 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9566459B2 (en) 2013-07-16 2017-02-14 Beijing Mechanical Equipment Institute Fire engine suitable for fire-fighting in high-rise and super high-rise buildings
US9806963B2 (en) 2013-10-18 2017-10-31 Cellco Partnership Feature activation on device
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024056923A (ja) * 2012-11-15 2024-04-23 アペリス・ファーマシューティカルズ・インコーポレイテッド 細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法

Also Published As

Publication number Publication date
EP2707384A4 (en) 2014-11-19
CA2835627A1 (en) 2012-11-15
JP2017155056A (ja) 2017-09-07
CN107050422A (zh) 2017-08-18
US20210292368A1 (en) 2021-09-23
JP6653294B2 (ja) 2020-02-26
WO2012155107A1 (en) 2012-11-15
RU2653439C2 (ru) 2018-05-08
IL304291A (en) 2023-09-01
JP6905554B2 (ja) 2021-07-21
DK2707384T3 (da) 2022-06-07
US11001610B2 (en) 2021-05-11
AU2019226186A1 (en) 2019-09-26
JP2014514364A (ja) 2014-06-19
MX385001B (es) 2025-03-14
RU2653439C9 (ru) 2018-10-16
AU2019226186B2 (en) 2021-04-01
IL229368B (en) 2019-03-31
US20140323407A1 (en) 2014-10-30
IL265344B2 (en) 2023-12-01
MX356528B (es) 2018-06-01
CA2835627C (en) 2023-01-10
IL265344A (en) 2019-05-30
AU2012253294B2 (en) 2017-07-20
AU2017245334A1 (en) 2017-11-02
MX2013013084A (es) 2014-01-31
EP2707384A1 (en) 2014-03-19
RU2013149956A (ru) 2015-06-20
US20240076317A1 (en) 2024-03-07
CN103687867B (zh) 2017-02-08
US20190241617A1 (en) 2019-08-08
EP2707384B1 (en) 2022-04-06
AU2012253294A1 (en) 2014-01-09
JP2019206547A (ja) 2019-12-05
IL229368A0 (en) 2014-01-30
BR112013028816B1 (pt) 2020-12-15
EP4105224A1 (en) 2022-12-21
CN103687867A (zh) 2014-03-26
CN107050422B (zh) 2021-11-09
IL265344B1 (en) 2023-08-01
BR112013028816A2 (pt) 2016-11-29
US10125171B2 (en) 2018-11-13
US11661441B2 (en) 2023-05-30
ES2915265T3 (es) 2022-06-21
AU2017245334B2 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JP6522337B2 (ja) 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP7093871B2 (ja) 細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法
KR20240135047A (ko) 투여 요법 및 관련 조성물 및 방법
HK40085306A (en) Long-acting compstatin analogs and uses thereof
HK1243917A1 (en) Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
HK1243917B (zh) 细胞反应性的，长效的或靶向的坎普他汀类似物及其用途
HK1195780B (en) Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
HK1195780A (en) Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180813

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190424

R150 Certificate of patent or registration of utility model

Ref document number: 6522337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250